Stockreport

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Target enrollment achieved in RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, strengthening confidence in clinical timelin [Read more]